4. Primary lateral sclerosis Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 7 /  Drugs : 20 - (DrugBank : 5) / Drug target genes : 16 - Drug target pathways : 28

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
ALS medications and other medications
   Healing Advocates Registry and Ministry
      2026   -   NCT07233148   United States
Dalfampridine
   Hospital for Special Surgery, New York
      2016   Phase 1   NCT02868567   United States
Daraprim
   Weill Medical College of Cornell University
      2013   -   EUCTR2011-004798-99-DE   Germany;Italy;United States
Dexdor
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland
Dexmedetomidine
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland
Diet, various diets will BE observed
   Healing Advocates Registry and Ministry
      2026   -   NCT07233148   United States
Education about treatment options
   Healing Advocates Registry and Ministry
      2026   -   NCT07233148   United States
Esketamine
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland
Exercise, physical therapy, occupational therapy, speech therapy, sauna, EMS, massage and other therapies
   Healing Advocates Registry and Ministry
      2026   -   NCT07233148   United States
HB-admscs
   Hope Biosciences Research Foundation
      2021   -   NCT04825613   United States
Ketanest-S
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland
Levetiracetam
   Duke University
      2006   Phase 2   NCT00324454   United States
Physical and emotional support
   Healing Advocates Registry and Ministry
      2026   -   NCT07233148   United States
Pyrimethamine
   Weill Medical College of Cornell University
      2013   -   EUCTR2011-004798-99-DE   Germany;Italy;United States
Stem cells
   Stem Cells Arabia
      2016   Phase 1/Phase 2   NCT03067857   -